Protagonist Therapeutics (PTGX) Stock Price

Protagonist Therapeutics Price

NASDAQ·CLOSED
151.42USD-0.19 (-0.13 %)
Market closed

Over the last 8 years Protagonist Therapeutics grew revenue by 10.9% annually, reaching 46.02 M USD. For Protagonist Therapeutics, the net margin of -282.8% is up versus -458.9% a few years ago. The consensus 12-month price target for Protagonist Therapeutics is 104.04 USD, about 31.3% below where the stock trades today. Of 19 analysts, 17 rate the stock a buy — an overall Buy consensus. The stock trades about 170% above its 52-week low.

Protagonist Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Protagonist Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Protagonist Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Protagonist Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Protagonist Therapeutics Stock Price History
DateProtagonist Therapeutics Price
8/13/2026151.42 USD
8/12/2026151.61 USD
8/10/2026148.12 USD
8/7/2026145.87 USD
8/6/2026146.18 USD
8/5/2026136.12 USD
8/4/2026134.37 USD
8/3/2026132.28 USD
7/31/2026136.64 USD
7/30/2026138.64 USD
7/29/2026137.38 USD
7/27/2026138.05 USD
7/23/2026135.43 USD
7/22/2026135.44 USD
7/21/2026138.31 USD
7/20/2026134.27 USD
7/17/2026140.91 USD
7/16/2026132.02 USD
7/15/2026135.46 USD
7/14/2026131.27 USD
7/13/2026129.60 USD
7/10/2026131.42 USD
7/9/2026137.64 USD
7/8/2026138.91 USD
7/7/2026140.85 USD
7/6/2026129.21 USD
7/2/2026131.62 USD
7/1/2026125.17 USD
6/30/2026122.58 USD
6/29/2026119.13 USD
6/26/2026121.88 USD
6/25/2026122.63 USD
6/24/2026122.15 USD
6/23/2026118.96 USD
6/22/2026114.60 USD
6/18/2026112.14 USD
6/17/2026112.76 USD
6/16/2026109.25 USD
6/15/2026111.26 USD
6/12/2026111.22 USD
6/11/2026109.52 USD
6/10/2026107.20 USD
6/9/2026105.87 USD
6/8/202698.03 USD
6/5/202698.50 USD
6/4/2026101.15 USD
6/3/202694.62 USD
6/2/202695.00 USD
6/1/202695.69 USD
5/29/202699.41 USD
5/28/2026101.32 USD
5/27/202699.97 USD
5/26/2026100.22 USD
5/22/2026100.53 USD
5/21/202698.92 USD
5/20/2026100.40 USD
5/19/202698.37 USD
5/18/2026100.74 USD
5/15/2026102.18 USD
5/14/2026105.55 USD
5/13/2026103.88 USD
5/12/202699.95 USD
5/11/2026103.50 USD
5/8/202699.36 USD
5/7/202698.85 USD
5/6/2026103.97 USD
5/5/202699.21 USD
5/4/202699.52 USD
5/1/202698.37 USD
4/30/202698.97 USD
4/29/202698.52 USD
4/28/2026101.21 USD
4/27/202698.51 USD
4/24/2026100.00 USD
4/23/2026102.62 USD
4/22/2026105.55 USD
4/21/2026105.89 USD
4/20/2026105.47 USD
4/17/2026105.98 USD
4/16/2026103.73 USD
4/15/2026105.44 USD
4/14/2026104.72 USD
4/13/202697.57 USD
4/10/202698.82 USD
4/9/2026104.09 USD
4/8/2026102.09 USD
4/7/2026103.75 USD
4/6/2026102.89 USD
4/2/2026103.78 USD
4/1/2026103.67 USD
3/31/2026105.40 USD
3/30/202699.87 USD
3/27/202698.97 USD
3/26/2026102.17 USD
3/25/2026104.31 USD
3/24/2026100.39 USD
3/23/202698.54 USD
3/20/202698.87 USD
3/19/2026101.68 USD
3/18/202697.09 USD
3/17/202697.23 USD
3/16/202696.75 USD
3/13/202692.36 USD
3/12/202695.42 USD
3/11/202696.48 USD
3/10/202697.05 USD
3/9/202696.66 USD
3/6/202692.09 USD
3/5/202691.41 USD
3/4/202694.83 USD
3/3/202691.30 USD
3/2/202694.24 USD
2/27/202692.08 USD
2/26/202688.39 USD
2/25/202687.10 USD
2/24/202687.39 USD
2/23/202686.59 USD
2/20/202682.76 USD
2/19/202683.09 USD
2/18/202682.99 USD
2/17/202682.46 USD
2/13/202681.49 USD
2/12/202681.93 USD
2/11/202683.49 USD
2/10/202683.88 USD
2/9/202683.32 USD
2/6/202684.49 USD
2/5/202680.67 USD
2/4/202683.30 USD
2/3/202685.59 USD
2/2/202683.05 USD
1/30/202681.80 USD
1/29/202679.73 USD
1/28/202681.76 USD
1/27/202683.08 USD
1/26/202682.30 USD
1/23/202683.10 USD
1/22/202684.79 USD
1/21/202683.89 USD
1/20/202683.42 USD
1/16/202681.99 USD
1/15/202684.75 USD
1/14/202685.23 USD
1/13/202681.36 USD
1/12/202680.25 USD
1/9/202680.22 USD
1/8/202680.20 USD
1/7/202682.34 USD
1/6/202682.27 USD
1/5/202684.18 USD
1/2/202687.18 USD
12/31/202587.34 USD
12/30/202587.26 USD
12/29/202587.93 USD
12/26/202588.78 USD
12/24/202588.84 USD
12/23/202588.73 USD
12/22/202587.41 USD
12/19/202586.05 USD
12/18/202585.79 USD
12/17/202589.34 USD
12/16/202591.54 USD
12/15/202594.79 USD
12/12/202595.35 USD
12/11/202592.25 USD
12/10/202591.38 USD
12/9/202588.56 USD
12/8/202590.25 USD
12/5/202589.65 USD
12/4/202587.33 USD
12/3/202586.07 USD
12/2/202584.65 USD
12/1/202585.64 USD
11/28/202590.00 USD
11/26/202590.07 USD
11/25/202589.86 USD
11/24/202587.69 USD
11/21/202585.40 USD
11/20/202584.20 USD
11/19/202585.13 USD
11/18/202584.39 USD
11/17/202584.77 USD
11/14/202584.61 USD
11/13/202583.24 USD
11/12/202584.85 USD
11/11/202585.56 USD
11/10/202583.23 USD
11/7/202579.54 USD
11/6/202579.78 USD
11/5/202577.88 USD
11/4/202576.50 USD
11/3/202575.95 USD
10/31/202578.62 USD
10/30/202577.85 USD
10/29/202576.69 USD
10/28/202578.51 USD
10/27/202575.25 USD
10/24/202574.86 USD
10/23/202573.99 USD
10/22/202573.50 USD
10/21/202575.00 USD
10/20/202576.72 USD
10/17/202577.50 USD
10/16/202575.73 USD
10/15/202577.68 USD
10/14/202576.94 USD
10/13/202579.17 USD
10/10/202587.00 USD
10/9/202567.04 USD
10/8/202565.30 USD
10/7/202565.47 USD
10/6/202564.14 USD
10/3/202564.83 USD
10/2/202564.98 USD
10/1/202564.00 USD
9/30/202566.43 USD
9/29/202565.14 USD
9/26/202567.42 USD
9/25/202564.70 USD
9/24/202565.95 USD
9/23/202565.06 USD
9/22/202564.51 USD
9/19/202562.20 USD
9/18/202562.14 USD
9/17/202559.22 USD
9/16/202558.59 USD
9/15/202558.38 USD
9/12/202558.86 USD
9/11/202559.68 USD
9/10/202557.74 USD
9/9/202558.36 USD
9/8/202556.19 USD
9/5/202560.53 USD
9/4/202559.60 USD
9/3/202558.11 USD
9/2/202558.85 USD
8/29/202559.05 USD
8/28/202558.14 USD
8/27/202561.43 USD
8/26/202556.99 USD
8/25/202556.88 USD
8/22/202557.48 USD
8/21/202556.04 USD
8/20/202556.23 USD
8/19/202556.25 USD
8/18/202556.21 USD
Access this data via the Eulerpool API
Get Free API Key

Protagonist Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
60.00 M USD
-93.65 M USD
-78.96 M USD
Jan 1, 2024
434.43 M USD
252.84 M USD
275.19 M USD
Jan 1, 2025
46.02 M USD
-158.13 M USD
-130.15 M USD
Jan 1, 2026 (e)
542.29 M USD
-352.25 M USD
302.28 M USD
Jan 1, 2027 (e)
200.26 M USD
-118.31 M USD
-8.89 M USD
Jan 1, 2028 (e)
351.14 M USD
-235.74 M USD
95.57 M USD
Jan 1, 2029 (e)
594.04 M USD
-398.82 M USD
284.81 M USD
Jan 1, 2030 (e)
888.46 M USD
-596.48 M USD
494.92 M USD

Protagonist Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 16, 2026, 6:11 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
––20.0030.00–28.0027.0026.0060.00434.0046.00542.00200.00351.00594.00888.00
–––50.00––-3.57-3.70130.77623.33-89.401,078.26-63.1075.5069.2349.49
––100.00100.00–100.00100.00100.00100.00100.0095.6595.6595.6595.6595.6595.65
44.0044.0020.0030.0044.0028.0027.0026.0060.00434.0044.00518.43191.30335.74568.17849.39
-14.00-32.00-37.00-42.00-80.00-64.00-125.00-131.00-93.00252.00-158.00-352.00-118.00-235.00-398.00-596.00
––-185.00-140.00–-228.57-462.96-503.85-155.0058.06-343.48-64.94-59.00-66.95-67.00-67.12
-14.00-37.00-36.00-38.00-77.00-66.00-125.00-123.00-78.00275.00-130.00302.00-8.0095.00284.00494.00
27.27164.29-2.705.56102.63-14.2989.39-1.60-36.59-452.56-147.27-332.31-102.65-1,287.50198.9573.94
5.8816.7220.2024.1927.6139.6148.1549.2661.8066.4163.5763.5763.5763.5763.5763.57
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Protagonist Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Protagonist Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Protagonist Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Protagonist Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Protagonist Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Protagonist Therapeutics stock margins

The Protagonist Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Protagonist Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Protagonist Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
100.00 %
-460.01 %
-458.94 %
Jan 1, 2022
100.00 %
-494.24 %
-464.29 %
Jan 1, 2023
100.00 %
-156.09 %
-131.59 %
Jan 1, 2024
100.00 %
58.20 %
63.34 %
Jan 1, 2025
97.34 %
-343.63 %
-282.83 %
Jan 1, 2026 (e)
97.34 %
-64.96 %
55.74 %
Jan 1, 2027 (e)
97.34 %
-59.08 %
-4.44 %
Jan 1, 2028 (e)
97.34 %
-67.14 %
27.22 %

Protagonist Therapeutics Stock Revenue, EBIT, Earnings per Share

The Protagonist Therapeutics earnings per share therefore indicates how much revenue Protagonist Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.57 USD
-2.61 USD
-2.61 USD
Jan 1, 2022
0.54 USD
-2.67 USD
-2.51 USD
Jan 1, 2023
0.97 USD
-1.52 USD
-1.28 USD
Jan 1, 2024
6.54 USD
3.81 USD
4.14 USD
Jan 1, 2025
0.72 USD
-2.49 USD
-2.05 USD
Jan 1, 2026 (e)
8.53 USD
-5.54 USD
4.75 USD
Jan 1, 2027 (e)
3.15 USD
-1.86 USD
-0.14 USD
Jan 1, 2028 (e)
5.52 USD
-3.71 USD
1.50 USD

Protagonist Therapeutics business model & stock analysis

Protagonist Therapeutics Inc is a biopharmaceutical company focused on the development and commercialization of novel peptide therapies. The company was founded in 2002 and is headquartered in Newark, California. The history of Protagonist Therapy began with the discovery of a new type of molecules called peptides, which can be used as potential drugs for various diseases. This discovery was the result of years of research and collaboration between academics and leading pharmaceutical companies. Protagonist Therapeutics' business model is focused on developing and distributing new peptide therapies in the pharmaceutical industry. The company works closely with leading academics and biotechnology companies to advance its research and development projects. Protagonist Therapeutics is divided into several divisions focusing on different therapeutic areas. These include gastrointestinal diseases, immunology, and oncology. Each division works on developing new peptide therapies specifically tailored to their respective therapeutic areas. One example of a product from Protagonist Therapeutics is PTG-300, which was developed for the treatment of iron deficiency anemia. PTG-300 is a synthetic peptide that promotes increased iron uptake in the body to combat iron deficiency. Another product from Protagonist Therapeutics is PTG-200, which was developed for the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. PTG-200 is a peptide that blocks the action of certain enzymes that amplify inflammation in the intestine. Overall, Protagonist Therapeutics aims to establish itself as a leading provider of peptide therapies in the pharmaceutical industry. The company has a strong financial foundation, including a successful IPO in 2016, and is continuously working on developing new products to expand and grow the company.

Protagonist Therapeutics SWOT Analysis

Strengths

[ { "heading": "1.", "text": "Innovative" }, { "heading": "2.", "text": "Strong" }, { "heading": "3.", "text": "Well-established" }, { "heading": "4.", "text": "Diverse" }, { "heading": "5.", "text": "Experienced" } ]

Weaknesses

[ { "heading": "1.", "text": "Relatively" }, { "heading": "2.", "text": "High" }, { "heading": "3.", "text": "Limited" }, { "heading": "4.", "text": "Vulnerability" }, { "heading": "5.", "text": "Intense" } ]

Opportunities

[ { "heading": "1.", "text": "Growing" }, { "heading": "2.", "text": "Expansion" }, { "heading": "3.", "text": "Increasing" }, { "heading": "4.", "text": "Emerging" }, { "heading": "5.", "text": "Advancements" } ]

Threats

[ { "heading": "1.", "text": "Stringent" }, { "heading": "2.", "text": "Risk" }, { "heading": "3.", "text": "Intellectual" }, { "heading": "4.", "text": "Economic" }, { "heading": "5.", "text": "Potential" } ]

Protagonist Therapeutics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Protagonist Therapeutics Employees
Details
Date
Protagonist Therapeutics Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Protagonist Therapeutics Segments

Protagonist Therapeutics Revenue by Segment

  • 3 Years

  • 5 Years

  • Max

Financial Service Other
Details
Date
Financial Service Other
Jan 1, 2018
100,000.00 USD

Protagonist Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Protagonist Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Protagonist Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Protagonist Therapeutics shares outstanding

The number of shares of Protagonist Therapeutics was 63.57 M in 2025. This indicates how many shares Protagonist Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
48.15 M Stocks
Jan 1, 2022
49.26 M Stocks
Jan 1, 2023
61.80 M Stocks
Jan 1, 2024
66.41 M Stocks
Jan 1, 2025
63.57 M Stocks
Jan 1, 2026 (e)
63.57 M Stocks
Jan 1, 2027 (e)
63.57 M Stocks
Jan 1, 2028 (e)
63.57 M Stocks

Current Protagonist Therapeutics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
89.47 % (17)
Hold
10.53 % (2)
Sell
0.00 % (0)
12M Price Target
104.04
Last Price
155.10
Currency
USD
12M Return Potential
-32.92 %
LTM Return
0 %

Protagonist Therapeutics Analyst Rating Actions

DateFirmActionRatingReliability
7/14/2026
Barclays
Barclays
MaintainedOverweight33
7/7/2026
Truist Securities
Truist Securities
MaintainedBuy–
5/6/2026
Wedbush
Wedbush
MaintainedOutperform59
5/6/2026
Citizens
Citizens
MaintainedMarket Outperform–
4/15/2026
Truist Securities
Truist Securities
MaintainedBuy–
4/7/2026
Clear Street
Clear Street
MaintainedBuy–
3/19/2026
Leerink Partners
Leerink Partners
MaintainedOutperform–
3/19/2026
JP Morgan
JP Morgan
MaintainedOverweight80
3/19/2026
Citigroup
Citigroup
MaintainedBuy48
3/19/2026
Barclays
Barclays
MaintainedOverweight33

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Protagonist Therapeutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/4/20261.99USD-216.68 MUSD-2026 Q2
5/4/2026-0.49USD-16.60 MUSD-2026 Q1
2/19/2026-0.54USD-9.10 MUSD-2025 Q4
5/2/2024-0.65USD-0.00USD-2024 Q1
3/13/20240.00USD-39.10 MUSD-2023 Q4
8/2/2023-0.72USD-1.27 MUSD-2023 Q2
5/2/2023-0.70USD-2.54 MUSD-2023 Q1
2/27/2023-0.65USD-5.07 MUSD-2022 Q4
11/8/2022-0.89USD-0.00USD-2022 Q3
8/4/2022-0.95USD-389,079.00USD-2022 Q2

EESG©

Eulerpool ESG Scorecard© for the Protagonist Therapeutics stock

46/100
18
Environment
99
Social
21
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees50
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Protagonist Therapeutics shareholder structure

% Name
15.38287%
BLACKROCK, INC.
BLACKROCK, INC.
13.09284%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
9.98678%
FARALLON CAPITAL MANAGEMENT LLC
FARALLON CAPITAL MANAGEMENT LLC
9.66447%
Farallon Capital Management, L.L.C.
Farallon Capital Management, L.L.C.
8.49759%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
8.14463%
UBS GROUP AG
UBS GROUP AG
...

Protagonist Therapeutics Beneficial Ownership Filings (SEC 13D/G)

Free Float
81.6%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
46.00%
Constellation Brands, Inc.
Constellation Brands, Inc.
SEC ↗
13.80%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
9.04%
Roderick Wong
Roderick Wong
SEC ↗
9.00%
William Seybold
William Seybold
SEC ↗
9.00%
Thomas G. Roberts, Jr.
Thomas G. Roberts, Jr.
SEC ↗
9.00%
Richard B. Fried
Richard B. Fried
SEC ↗
9.00%
Rajiv A. Patel
Rajiv A. Patel
SEC ↗
9.00%
Philip D. Dreyfuss
Philip D. Dreyfuss
SEC ↗
9.00%
Michael G. Linn
Michael G. Linn
SEC ↗
9.00%
Michael B. Fisch
Michael B. Fisch
SEC ↗

Protagonist Therapeutics Executives and Management Board

10 members · avg. age 65 · 10 % women

DP

Dr. Dinesh Patel (68)

President, Chief Executive Officer, Director · since 2008

9.47 M USD

Management

AM

Dr. Arturo Molina (66)

Chief Medical Officer

3.46 M USD
AA

Mr. Asif Ali (51)

Chief Financial Officer, Executive Vice President

2.81 M USD
SG

Mr. Suneel Gupta (66)

Executive Vice President - Clinical Development

2.74 M USD
CD

Mr. Corey Davis

IR Contact Officer · since 2024

–

Board of Directors

HS

Dr. Harold Selick (70)

Independent Chairman of the Board

571,734.00 USD
WW

Mr. William Waddill (68)

Independent Director

540,484.00 USD
BG

Mr. Bryan Giraudo (49)

Independent Director

532,984.00 USD
LW

Dr. Lewis Williams (75)

Independent Director

530,484.00 USD
SO

Ms. Sarah O'Dowd (75)

Independent Director

523,283.00 USD

Protagonist Therapeutics Supply Chain

Protagonist Therapeutics Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#Nameβ 1YTrend
1
Johnson & Johnson
Supplier·Customer·Pharmaceuticals·US
0.78
0.18
-0.78
-0.76
-0.34
0.34
-0.14
2
Ligand Pharmaceuticals
Supplier·Biotechnology·US
0.66
0.81
0.88
0.84
0.39
0.33
—
#Nameβ 1YTrend
1
Zealand Pharma
Supplier·Biotechnology·DK
-0.79
-0.37
0.60
0.83
0.66
-0.02
1.39

Frequently asked questions about Protagonist Therapeutics

The business model of Protagonist Therapeutics Inc revolves around developing and commercializing peptide-based drugs for the treatment of gastrointestinal diseases and disorders. Protagonist Therapeutics Inc focuses on discovering and designing potential drug candidates to target certain biological pathways and address unmet medical needs. By leveraging its proprietary technology platform, the company aims to advance innovative therapies that have the potential to improve outcomes for patients suffering from various gastrointestinal conditions. With a strong focus on research and development, Protagonist Therapeutics Inc aims to bring novel treatments to market that can positively impact the lives of those affected by gastrointestinal diseases.

Protagonist Therapeutics Inc is primarily active in the pharmaceutical industry.

The main competitors of Protagonist Therapeutics Inc in the market include companies such as Amgen Inc, Gilead Sciences Inc, Pfizer Inc, and Roche Holding AG.

Protagonist Therapeutics Inc. is a biopharmaceutical company specializing in the development of peptide-based drugs. Founded in 2006, the company is headquartered in Newark, California. Protagonist Therapeutics Inc. focuses on discovering and developing novel therapeutics for the treatment of various diseases, including inflammatory bowel disease (IBD), gastrointestinal (GI) disorders, and other serious conditions. The company utilizes its proprietary peptide technology platform to design and optimize peptide drugs, aiming to provide targeted and effective treatments for patients in need. With a strong commitment to innovation and clinical research, Protagonist Therapeutics Inc. continues to strive towards advancing the field of peptide-based therapeutics for improved patient outcomes.

Protagonist Therapeutics Inc has achieved several significant milestones in its journey. The company successfully completed Phase 2 clinical trials for its potential drug PTG-100, which showed promising results in treating ulcerative colitis. Additionally, Protagonist Therapeutics Inc entered a partnership with Janssen Biotech to develop and commercialize PTG-200 for the treatment of Crohn's disease. Moreover, the company received Fast Track designation from the U.S. FDA for PTG-200, highlighting its potential in addressing unmet medical needs. Protagonist Therapeutics Inc's dedication to advancing novel therapeutic options marks a commendable achievement in the field of biotechnology.

Protagonist Therapeutics Inc is primarily present in the United States.

Protagonist Therapeutics Inc is a biopharmaceutical company that is driven by a strong set of values and corporate philosophy. They are committed to discovering and developing innovative peptide-based therapeutics that have the potential to transform patients' lives. With a focus on developing first-in-class oral peptide drugs, Protagonist Therapeutics Inc strives to provide novel treatment options for patients suffering from serious diseases. Their corporate philosophy revolves around collaboration, innovation, and scientific excellence, aiming to deliver value to patients, healthcare providers, and stakeholders. By combining cutting-edge research and an unwavering dedication to patient-centered solutions, Protagonist Therapeutics Inc embodies a commitment to advancing healthcare.

Analysts currently set an average price target of 102.55 USD for the Protagonist Therapeutics stock (median: 104.04 USD), implying -33.9 % versus the latest price. The consensus is based on 19 analyst ratings.

Protagonist Therapeutics Analyst Price Targets 2026

19 analysts currently rate the Protagonist Therapeutics stock: 17 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Protagonist Therapeutics to generate revenue of 542.29 M USD and earnings per share of 4.75 USD.

Protagonist Therapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the Protagonist Therapeutics share trades at 130.94 EUR (151.42 USD).

The Protagonist Therapeutics share (PTGX) is listed on 1 stock exchanges, including: NASDAQ (PTGX).

Protagonist Therapeutics Inc. is a biotechnology company specializing in the development of peptide therapeutics for the treatment of diseases. The company's business model aims to promote the research and development of peptide drugs through novel approaches such as proteolysis to achieve higher effectiveness for patients.

The expected revenue of Protagonist Therapeutics is 542.29 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Protagonist Therapeutics is 302.28 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Protagonist Therapeutics is currently 31.85. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Protagonist Therapeutics stock.

The price-to-sales ratio (P/S) of Protagonist Therapeutics is currently 17.75. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Protagonist Therapeutics stock.

The Eulerpool Quality Score for Protagonist Therapeutics is 3/10.

The ISIN of Protagonist Therapeutics is US74366E1029. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Protagonist Therapeutics is A2AP32. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Protagonist Therapeutics is PTGX. The ticker symbol is used to trade Protagonist Therapeutics shares on the stock exchange.

Protagonist Therapeutics paid dividends every year for the past 0 years.

Protagonist Therapeutics is assigned to the 'Health' sector.

The dividends of Protagonist Therapeutics are distributed in USD.

All fundamentals and in-depth analysis of Protagonist Therapeutics

Our stock analysis for Protagonist Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Protagonist Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Protagonist Therapeutics Stock
Protagonist Therapeutics Revenue→
Protagonist Therapeutics Stock
Protagonist Therapeutics Net Income→
Protagonist Therapeutics Stock
Protagonist Therapeutics P/E→
Protagonist Therapeutics Stock
Protagonist Therapeutics P/S→
Protagonist Therapeutics Stock
Protagonist Therapeutics EBIT→
Protagonist Therapeutics Stock
Protagonist Therapeutics Dividend→
Protagonist Therapeutics Stock
Protagonist Therapeutics Directors Dealings→
Protagonist Therapeutics Stock
Protagonist Therapeutics Stocks→
Protagonist Therapeutics Stock
Protagonist Therapeutics Market capitalization→
Protagonist Therapeutics Stock
Protagonist Therapeutics Debt→
Protagonist Therapeutics Stock
Protagonist Therapeutics Liabilities→
Protagonist Therapeutics Stock
Protagonist Therapeutics Equity→
Protagonist Therapeutics Stock
Protagonist Therapeutics AAQS→
Protagonist Therapeutics Stock
Protagonist Therapeutics Employees→
Protagonist Therapeutics Stock
Protagonist Therapeutics ROE→
Protagonist Therapeutics Stock
Protagonist Therapeutics ROA→
Protagonist Therapeutics Stock
Protagonist Therapeutics ROCE→
Protagonist Therapeutics Stock
Protagonist Therapeutics News→
Protagonist Therapeutics Stock
Protagonist Therapeutics Analyst Price Targets→

Health Stocks

Protalix BiotherapeuticsProtagenic TherapeuticsProtara TherapeuticsProstatype GenomicsProtect Pharmaceutical CorporationProQR TherapeuticsProteina CoProphase LabsProteome SciencesPropanc BiopharmaProteomics International LaboratoriesPromisia HealthcareAll Stocks A–Z →